FDA approves World’s first RSV Vaccine
The initial RSV vaccine was given the go light by the Food and Drug Administration on Wednesday. Results from the Trial According to trial results, Arexvy, a novel vaccine created by GSK, formerly known as GlaxoSmithKline, was 82% effective in preventing lower respiratory tract illnesses brought on by RSV in persons 60 and older. Additionally, it had a 94% success rate in patients with at least one underlying medical condition. Dr. Peter Marks, director of the FDA’s Centre for Biologics Evaluation and Research, said, “Today’s approval of the first RSV vaccine is an important public health achievement to prevent a disease which can be life-threatening and reflects the FDA’s continued commitment to facilitating the development of safe and effective vaccines for use in the United States.” By the age of two, almost everyone has respiratory syncytial virus, which typically causes cold symptoms. However, it’s also the main reason why infants and young children are admitte...